Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown

Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell treatment reduced the most painful complications of the blood disease for a full year.